1
|
Byun SH, Lee JH, Jung NC, Choi HJ, Song JY, Seo HG, Choi J, Jung SY, Kang S, Choi YS, Chung JH, Lim DS. Rosiglitazone-mediated dendritic cells ameliorate collagen-induced arthritis in mice. Biochem Pharmacol 2016; 115:85-93. [PMID: 27208887 DOI: 10.1016/j.bcp.2016.05.009] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2016] [Accepted: 05/17/2016] [Indexed: 10/21/2022]
Abstract
Rosiglitazone is a selective ligand for peroxisome proliferator-activated receptor-gamma (PPAR-γ), which serves diverse biological functions. A number of autoimmune disease models have been used to examine the anti-inflammatory and immunosuppressive effects of tolerogenic dendritic cells (tDCs). The aim of the present study was to investigate whether rosiglitazone-mediated DC (Rosi-DC) therapy suppressed arthritis in a collagen-induced arthritis (CIA) mouse model. Rosi-DCs were generated by treating immature DCs with TNF-α, type II collagen, and rosiglitazone. CIA mice then received subcutaneously (s.c.) two injections of Rosi-DCs. The severity of arthritis was then assessed histopathologically. The phenotypes of the DC and regulatory T (Treg) cell populations in CIA mice were determined by flow cytometry and the effect of Rosi-DCs on the secretion of autoimmunity-inducing cytokines was examined by ELISA. Rosi-DCs expressed lower levels of DC-related surface markers than mature DCs. Histopathological examination revealed that the degree of inflammation in the paws of Rosi-DC-treated mice was much lower than that in the paws of PBS-treated CIA mice. Taken together, these results clearly show that rosiglitazone-mediated DCs ameliorate CIA, most likely via the induction of antigen-specific Treg cells.
Collapse
Affiliation(s)
- Sei-Hee Byun
- Department of Biotechnology, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 463-400, Republic of Korea
| | - Jun-Ho Lee
- Department of Biotechnology, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 463-400, Republic of Korea; Pharos Vaccine Inc., 545 Dunchon-daero, Jungwon-gu, Seongnam, Gyeonggi-do 462-807, Republic of Korea
| | - Nam-Chul Jung
- Pharos Vaccine Inc., 545 Dunchon-daero, Jungwon-gu, Seongnam, Gyeonggi-do 462-807, Republic of Korea
| | - Hyun-Ji Choi
- Department of Biotechnology, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 463-400, Republic of Korea
| | - Jie-Young Song
- Department of Radiation Cancer Sciences, Korea Institute of Radiological and Medical Sciences, 215-4 Gongneung-dong, Nowon-gu, Seoul 139-706, Republic of Korea
| | - Han Geuk Seo
- Department of Animal Biotechnology, Konkuk University, 1 Hwayang-dong, Gwangjin-gu, Seoul 143-701, Republic of Korea
| | - Jinjung Choi
- Division of Rheumatology, Bundang CHA Medical Center, Yatap-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-712, Republic of Korea
| | - Sang Youn Jung
- Division of Rheumatology, Bundang CHA Medical Center, Yatap-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-712, Republic of Korea
| | - Sangjin Kang
- Department of Biotechnology, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 463-400, Republic of Korea
| | - Yong-Soo Choi
- Department of Biotechnology, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 463-400, Republic of Korea
| | - Ji Hyung Chung
- Department of Biotechnology, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 463-400, Republic of Korea
| | - Dae-Seog Lim
- Department of Biotechnology, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 463-400, Republic of Korea.
| |
Collapse
|
2
|
Lim DS, Kang MS, Jeong JA, Bae YS. Semi-mature DC are immunogenic and not tolerogenic when inoculated at a high dose in collagen-induced arthritis mice. Eur J Immunol 2009; 39:1334-43. [PMID: 19350558 DOI: 10.1002/eji.200838987] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Semi-mature DC (smDC) have been shown to be tolerogenic and thus applicable to the treatment of autoimmune disease. However, in our repeated experiments, even the same batches of smDC were found to be profoundly immunogenic rather than tolerogenic when inoculated at high doses into arthritic mice. In a cytokine chip assay, smDC were characterized by remarkable production of IL-2, IL-3, IL-5, and IL-13 together with well-known Th2 cytokines. Low doses (2 x 10(5)) of smDC showed excellent anti-arthritic activity in collagen-induced arthritis animals, whereas high doses (2 x 10(6)) of smDC uniformly accelerated arthritic symptoms. SmDC, vaccinated at lower doses, markedly induced forkhead box P3 Treg, Th2 cytokines (IL-4/IL-10), and TGF-â in their immune deviation. Interestingly, however, as the number of smDC increased from 2 x 10(5) to 2 x 10(6) in the same assay, the Treg population, Th2 cytokines, and TGF-beta were dramatically reduced. Our present study clearly indicates that smDC could induce either T-cell tolerance or T-cell activation, depending on the inoculum size. Special attention should be paid to the optimal range of smDC in DC-mediated immunotherapy for the treatment of rheumatoid arthritis.
Collapse
Affiliation(s)
- Dae-Seog Lim
- Research Institute for DC Immunotherapy, CreaGene Inc., 2F Jungang Induspia V, Sangdaewon-dong, Jungwon-gu, Seongnam-si, Gyeonggi-do, Korea
| | | | | | | |
Collapse
|
3
|
Zhang X, Kedl RM, Xiang J. CD40 ligation converts TGF-beta-secreting tolerogenic CD4-8- dendritic cells into IL-12-secreting immunogenic ones. Biochem Biophys Res Commun 2009; 379:954-8. [PMID: 19135981 DOI: 10.1016/j.bbrc.2008.12.179] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2008] [Accepted: 12/24/2008] [Indexed: 12/14/2022]
Abstract
CD40L, the ligand for CD40 on dendritic cells (DCs), plays an important role in maturation and activation of DCs leading to induction of immune responses. Our previous studies showed that the mouse splenic CD4(-)8(-) DCs are tolerogenic and capable of stimulating suppressive type 1 CD4(+) regulatory T (Tr1) cell responses via TGF-beta secretion. In this study, we investigated whether CD40 ligation is able to convert tolerogenic CD4(-)8(-) DCs into immunogenic ones by in vitro treatment of DCs with anti-CD40 antibody. Our data showed that in vitro CD40 ligation with anti-CD40 antibody converted TGF-beta-secreting tolerogenic CD4(-)8(-) DCs into IL-12-secreting immunogenic ones capable of stimulating type 1 CD4(+) helper T (Th1) and CD8(+) cytotoxic T lymphocyte (CTL) responses leading to induction of antitumor immunity. In addition, in vivo CD40 ligation by intratumoral injection of adenoviral vector AdVCD40L expressing CD40 ligand also induced tumor growth inhibition and regression of established P815 tumors with infiltration of tolerogenic CD4(-)8(-) DCs. Therefore, our data provide new information for and may thus have useful impacts in CD40 ligation-based immunotherapy of cancer.
Collapse
Affiliation(s)
- Xueshu Zhang
- Cancer Research Unit, Saskatchewan Cancer Agency and Departments of Oncology and Immunology, Pathology, University of Saskatchewan, 20 Campus Drive, Saskatoon, Saskatchewan S7N 0W0, Canada
| | | | | |
Collapse
|